Furthermore, immunohistochemistry of the tumor tissues targeting Ki67 protein, a cellular marker for proliferation showed that the Ki67 level significantly reduced in the drug treatment groups, compared to the vehicle group, with the lowest level in the combined treatment group (Figure 6C). Here, MKI67 is linked to neoplasm.